Israel - English - Ministry of Health

amgen europe b.v. - evolocumab - solution for injection - evolocumab 140 mg/ml - evolocumab - hypercholesterolaemia and mixed dyslipidaemiarepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, and in paediatric patients aged 10 years and over with heterozygous familial hypercholesterolaemia, as an adjunct to diet:• in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated. homozygous familial hypercholesterolaemia repatha is indicated in adults and paediatric patients aged 10 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.established atherosclerotic cardiovascular disease repatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering ldl-c levels, as an adjunct to correction of other risk factors:• in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 10 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 100 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 150 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age.aranesp ® is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 20 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 30 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 40 mcg / 0.4 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 50 mcg / 0.5 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 60 mcg / 0.3 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age

Israel - English - Ministry of Health

amgen europe b.v. - darbepoetin alfa - solution for injection - darbepoetin alfa 300 mcg / 0.6 ml - darbepoetin alfa - aranesp ® is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (crf) in adults and paediatric patients ≥ 1 year of age.aranesp ® is indicated for the treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.